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Summary objectives To ascertain the outcome of pre-Antiretroviral therapy (ART) and ART patients defaulting
from care and investigate reasons for defaulting.
methods Patients defaulting from HIV care in Chiradzulu between July 2004 and September 2007
were traced at last known home address. Deaths and moves were recorded, and patients found alive
were interviewed. Defaulting was deﬁned as missed last appointment by more than 1 month among
patients of unknown vital status.
results A total of 1637 individuals were traced (54%–88% of eligible), 981 pre-ART and 656
ART patients. Of 694 pre-ART patients found, 49% had died (51% of adults and 38% of children),
a median of 47 days after defaulting, and 14% had moved away. Of 451 ART patients found, 54%
had died (54% of adults and 50% of children), a median of 52 days after defaulting, and 20% had
moved away. Overall, 221 patients were interviewed (90% of those found alive), 42% had worked
outside the district in the previous year; 49% of pre-ART and 19% of ART patients had not disclosed
their HIV status to other household members. Main reasons for defaulting were stigma (43%), care
dissatisfaction (34%), improved health (28%) and for ART discontinuation, poor understanding of
disease or treatment (56%) and drug side effects (42%).
conclusion This study in a rural African HIV programme reveals the dynamics related to health
service access and use, and it provides information to correct programme mortality estimates for adults
and children.
keywords antiretroviral therapy, HIV, patient dropouts, sub-Saharan Africa
Introduction
Antiretroviral therapy (ART) has been scaled-up in Africa
over the past years (UNAIDS & WHO 2003, 2007). At
the end of 2007, 30% of the estimated 7 million people in
need of treatment were receiving it (WHO et al. 2009).
Satisfactory immuno-virological response and levels of
adherence to ART have been reported in African settings,
but evaluations are generally conducted among patients
remaining in HIV care (Ferradini et al. 2006; Mills et al.
2006; Spacek et al. 2006; Stringer et al. 2006; Toure et al.
2008). Nevertheless, high rates of loss to follow-up (LFU)
and ART discontinuation can greatly limit the effectiveness
of HIV programmes.
A recent meta-analysis summarized information from 17
studies that traced LFU adults receiving ART in resource-
limited settings (Brinkhof et al. 2009). Combined mortality
was estimated at 40% but ranged from 12% to 87% in
African studies. Reasons for defaulting were transfer to
another programme, ﬁnancial difﬁculty, and improved or
poor health. Surprisingly, there are limited or no data on
outcomes of pre-ART patients (Bassett et al. 2008; Toure
et al. 2008) or children LFU (Brinkhof et al. 2009). To
optimize care delivery, prevent treatment discontinuation
and monitor HIV programmes over time, it is necessary to
ascertainment patients’ outcomes and to identify reasons
for defaulting (Bisson et al. 2008).
Inthisstudy,wedescribetheoutcomesandreasonsforcare
discontinuation of pre-ART and ART adults and children
who defaulted from HIV care in Chiradzulu, Malawi.
Methods
Since 2001, Me ´decins Sans Frontie `res (MSF) has provided
free ART to patients infected with HIV in Chiradzulu, a
Malawian rural district, with an antenatal HIV prevalence
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delivered through one district hospital and 10 health
centres located 5–40 km from the hospital. Individual and
group counselling by community peers and trained advis-
ors are provided at ART start and during follow-up.
Clinical visits are scheduled every 6 months for pre-ART,
every 2–3 months for ART patients. Generic ﬁxed-dose
combinations of two nucleoside-reverse transcriptase
inhibitors and nevirapine or efavirenz are prescribed.
Medical information is routinely collected at every
consultation on standardized forms and entered in
FUCHIA (Epicentre, Paris, France). Data available are age,
sex, dates of enrolment, visits and appointments, visit
location, clinical stage, height, weight and, when
performed, CD4 cell count measurements.
Study design and procedures
As part of an internal audit of programme activities, we
conductedacross-sectionalstudytoascertainthevitalstatus
of defaulting patients. Eligibility criteria for participation
were programme enrolment between March 2001 and July
2007, residence in Chiradzulu district, and care discontin-
uation between July 2004 and September 2007. Patients
who missed their appointment by more than 1 month were
considered defaulters (programme deﬁnition).
All facility records were reviewed to maximize com-
pleteness of transfer and death events. Trained interviewers
made one to three home visits, recorded patient vital status
and reason for non-traceability. For patients found alive,
interviewers sought informed verbal consent and offered a
return-to-care appointment. For those who died or moved
away, family or community leaders were interviewed.
Standardized questionnaires translated into Chichewa and
back-translated into English were administered. Data
collected and entered into Access included date and place
of death or move and hospitalization after last recorded
clinic visit. To document reasons for care discontinuation
the question ‘Why did you stop attending the MSF clinic?’
followed by a number of dichotomous (yes⁄no) items were
asked. The term kusalidwa (‘to oppress’) was used to ask
whether stigma from community or family members was a
reason for care discontinuation.
District and traditional authorities were informed and
provided guidance to ensure patient conﬁdentiality. The
Malawi National Health Sciences Research Committee
granted approval for publication of results.
Statistical analysis
Patient characteristics (e.g. traced and untraced individu-
als) were compared using Student’s t-tests, Wilcoxon rank-
sum or chi-square tests, as appropriate. All analyses were
performed separately for pre-ART and ART patients using
stata 9.0 (StataCorp., College Station, TX, USA). Out-
comes were described by age group (children were aged
<15 years).
Results
As of July 2007, 19 626 patients were enrolled in the
Chiradzulu programme and 11 683 of them had started
ART (Figure 1). Between July 2004 and 2007, 3008
patients defaulted from care a median of 14.9 months after
enrolment: 1747 pre-ART (1561 adults and 186 children)
and 1261 ART patients (1186 adults and 75 children).
After excluding 1153 (38.3%) patients with missing
address information and 218 (7.2%) who lived outside
Chiradzulu, we traced 1637 individuals (54.0%–88.2% of
those eligible). Of these, 981 were pre-ART (874 adults
and 107 children) and 656 ART patients (624 adults and
32 children).
Patient vital status
We ascertained the vital status of 69.9% of traced patients.
Median time since default, 18.9 months [IQR 14.1–26.8]
for pre-ART and 23.2 months [IQR 14.4–35.1] for ART
patients, was shorter for individuals with ascertained
outcome than for other patients (21.7 vs. 26.8 months;
P < 0.001).
Of pre-ART adults traced, 626 (71.6%) were found, 226
(36.1%) were alive (64 of these were receiving care under
another identiﬁcation code), 317 (50.6%) dead and 83
(13.3%) had moved (Figure 2a). Of pre-ART children, 68
(63.6%) were found, 29 (42.7%) were alive, 26 (38.2%)
dead and 13 (19.1%) had moved (Figure 2B). Overall,
median time between last visit and death was 1.6 months
[IQR 0.6–7.1], and 46.8% of those who moved did so
within 3 months of last visit. Of ART adults, 429 (68.8%)
were found, 111 (25.9%) were alive (63 of these were still
receiving care), 233 (54.3%) dead and 85 (19.8%) had
moved. Of children traced, 22 (68.8%) were found, 8
(36.4%) were alive, 11 (50.0%) dead and 3 (13.6%) had
moved. Overall, median time between last consultation
and death was 1.7 months [IQR 0.6–8.0]. More than half
of those who moved did so within 3 months of last visit.
Patient characteristics at last medical visit
More than 50% of pre-ART patients discontinued care
within a month of programme inclusion. Median age at
last visit was 32 years and 61.2% were women (Table 1).
Characteristics of traced and untraced patients were
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decentralized care (72% vs. 54.5%). Patients found dead
had lower last recorded median BMI (17.9 and
20.4 kg⁄m
2) and CD4 cell counts (269 and 426 cells⁄mm
3)
than other patients.
For ART patients, median time on therapy before
defaulting was 7.6 months [IQR 1.4–19]. Characteristics
at last visit were similar in traced and untraced patients.
However, patients traced were receiving therapy for longer
(median 10.3 vs. 5.8 months) and were more frequently
followed in health centres (54.6% and 41.2%, respec-
tively). ART patients found dead had lower recorded BMI
(18.4 and 20.6 kg⁄m
2) and CD4 cell counts (160 and 215
cells⁄mm
3) than other patients.
Enrolled (n = 19 626) 
Pre-ART 
7943
ART
11 683
LFU between July 04 – July 07 (n = 3008) 
Pre-ART
1747
ART
1261
Traced (n = 1637) 
Pre-ART 
981
ART
656
Living outside Chiradzulu district 
Pre-ART
40
ART
178
No contact information
Pre-ART
726 
ART
427
Outcomes of tracing (n = 1637) 
Pre-ART
255 
343 
96 
287
ART
119 
244 
88 
205
Alive 
Dead 
Moved 
Not found 
Interviewed (n = 247) 
Pre-ART 
191
ART
56
Deaths and transfers
Pre-ART
125 
1 
248 
361 
ART
500 
3 
1006 
1099
Before July 04 
Dead 
Transfer 
July 04 – July 07 
Dead 
Transfer
On HIV care on 1
st July 07 
Pre-ART
3329
ART
7689
Figure 1 Study proﬁle and outcomes of patients enrolled in the HIV⁄AIDS care programme of Chiradzulu, Malawi, 2001–2007.
Note: LFU before July 2004 were 2132 pre-ART and 125 ART patients.
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defaulting
A total of 172 pre-ART (90.0% of those found alive) and
49 ART (87.5%) patients were interviewed (Table 2). Of
pre-ART respondents, 88.4% were adults and 66.3%
women. Fifty-one per cent reported to have disclosed their
HIV-seropositivity to other household members. Of ART
patients, 93.8% were adults and 73.5% women. Eighty-
one per cent had disclosed their HIV status to household
members, and 68.9% had stopped ART. Reasons for
therapy discontinuation were poor understanding of
disease, treatment (56.0%) and side effects (41.7%).
Overall, 41.5% of respondents had worked outside the
district in the previous year (Table 2). Forty-four per cent
lived more than 2 h from their HIV clinic, and 12.3% had
the resources required for travelling. Primary reasons for
defaulting were similar in pre-ART and ART patients:
stigma (42.5%), dissatisfaction with care or staff behaviour
(34.4%), perceived improved health (28.3%) and high
transportation cost (18.7%). Of the 161 pre-ART and 37
ART patients who scheduled a return appointment, 71%
and 65% sought care, respectively.
Discussion
In this evaluation of patients LFU in an HIV programme of
Malawi, 49% of pre-ART and 54% of ART patients had
died. Mortality was higher in adults than in children,
particularly among pre-ART patients (51% adults com-
pared to 38% in children). Reasons for defaulting were
dissatisfaction with care or staff behaviour, stigma and
poor understanding of disease and treatment.
We ascertained vital outcomes for 70% of traced
patients. Delays between defaulting and survey (75% of
patients were traced more than 1 year after their last
consultation and many discontinued care before 2006) and
seasonal or permanent migration (three of seven individ-
uals reported to have worked outside the district in the
previous year and one of six had moved) could explain
unsuccessful tracing. In Chiradzulu, the proportion of
patients followed under a different identiﬁcation code
(12%) and unrecorded transfers to another programme
(8%) were substantial. Better information of patients and
strengthening of referral systems could contribute to ensure
continuity of care and maximize recording of events. We
also found high mortality rates among pre-ART patients
defaulting from care, 51% in adults and 38% in children.
The observation that 61% of pre-ART patients had no
recorded CD4 measurements and almost 50% of dead
patients were eligible but not receiving ART, suggests that
patients in need of treatment are missed because of poor
screening or insufﬁcient education to identify severe
disease. The lower mortality rates seen in children should
be cautiously interpreted because greater proportions of
children than adults were not found (36% compared to
28% of adults) or had moved away (19% compared to
13%). Consistently with results of a recent meta-analysis
of sub-Saharan African programmes, where 39%–54% of
LFU adults had died (Brinkhof et al. 2009), in our
programme, half of defaulting ART adults and children
had died. Most deaths happened shortly after care
discontinuation and therapy initiation when mortality in
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Figure 2 Vital outcomes of pre-ART and ART adults and chil-
dren traced and found, HIV⁄AIDS programme of Chiradzulu,
Malawi, 2001–2007.
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Etard et al. 2006; Ferradini et al. 2006).
Eligibility for study participation was assessed for 62%
of LFU patients, and we determined the outcome of 70%
of those eligible. Patients not found defaulted longer ago
than those found, and as in previous studies (Yu et al.
2007; Maskew et al. 2007; Ive et al. 2005, Dalal et al.
2008), missing contact information or patient records
were the main reasons for exclusion. Because patients with
little family or social support might be less willing to
provide their address and those in good health more
likely to migrate in search of work, we could have
either overestimated or underestimated reported death
rates.
The main reason for LFU given by pre-ART and ART
patients was stigma, and 50% of pre-ART and 74% of
ART patients interviewed had not disclosed their HIV
status to household members. Previous research identiﬁed
fear of rejection and social isolation as reasons for care
discontinuation (Maskew et al. 2007; Yu et al. 2007;
Deribe et al. 2008) and barriers to treatment adherence
(Weiser et al. 2003; Mills et al. 2006; Yu et al. 2007). Our
study suggests that developing strategies to empower
patients to overcome these difﬁculties are needed even in
HIV highly prevalent areas like Chiradzulu. As in other
sub-Saharan contexts (Billy et al. 2007; Dalal et al. 2008;
Ive et al. 2005; Joshi et al. 2008; Maskew et al. 2007;
Muwanga et al. 2008; Yu et al. 2007), we found that
dissatisfaction with care or health personnel behaviour,
costly transportation, perceived improved health and drug
toxicity were important reasons for therapy discontinua-
tion. Dissatisfaction with health care and poor under-
standing of treatment commitment and medical follow-up
are likely to relate to high work load and task shifting with
insufﬁcient training and supervision. Open discussions
with personnel, supportive supervision and individual
patient counselling during follow-up could help to effec-
tively address these issues. Furthermore, despite decen-
tralization of care provision, many patients needed to walk
long distances or use costly transportation in Chiradzulu.
Evaluation of strategies such as implementation of longer
drug reﬁll periods and task shifting to trained lay care
providers for stable patients is therefore needed.
Conclusions
Monitoring and understanding programme retention
dynamics is essential for HIV programmes. Long-term
success of ART scale-up will require design and regular
evaluation of innovative strategies for patient support and
education and to improve programme access and quality of
care.
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Table 2 Reported socio-economic and
behavioural characteristics of pre-ART and
ART LFU patients interviewed, HIV⁄AIDS
programme of Chiradzulu, Malawi,
2001–2007
Pre-ART
N = 172
ART
N =4 9
Total
N = 221
Socio-economic factors*
Highest education level (%)
No education 23 (15.4) 5 (11.9) 28 (14.7)
Primary school 108 (72.5) 26 (61.9) 134 (70.2)
Secondary school 18 (12.1) 11 (26.2) 29 (15.2)
Missing – 1 1
Marital status (%)
Single 30 (20.3) 16 (38.1) 46 (24.2)
Married 95 (64.2) 14 (33.3) 109 (57.4)
Divorced⁄separated 13 (8.8) 5 (11.9) 18 (9.5)
Widowed 10 (6.8) 7 (16.7) 17 (8.9)
Missing 1 1 2
Employment (%)
Farmer 78 (54.2) 19 (50.0) 97 (53.3)
Housewife 34 (23.6) 8 (21.0) 42 (23.1)
Business 12 (8.3) 6 (15.8) 18 (9.9)
Other 20 (13.9) 5 (13.2) 25 (13.7)
Missing 5 5 10
Cost of travel to HIV care facility (%)
None 60 (36.8) 14 (32.6) 74 (35.9)
0.01–0.71 USD 47 (28.8) 13 (30.2) 60 (29.1)
‡0.72 USD 56 (34.4) 16 (37.2) 72 (34.9)
Missing 9 6 15
Travel time to HIV clinic (%)
<1 h 36 (21.8) 12 (28.6) 48 (23.2)
1–2 h 55 (33.3) 14 (33.3) 69 (33.3)
>2 h 74 (44.9) 16 (38.1) 90 (43.5)
Missing 7 7 14
Behavioural characteristics
Worked outside district in
past year (%)
59 (40.1) 19 (46.4) 78 (41.5)
Disclosed HIV status to
people living with (%)
77 (51.3) 34 (80.9) 111 (57.8)
Reasons for defaulting
Stigma 71 (45.8) 10 (25.0) 81 (42.5)
Transport cost 31 (20.1) 5 (12.8) 36 (18.7)
Unsatisﬁed with
care⁄staff behaviour
49 (31.6) 18 (45.0) 67 (34.4)
Inconvenient clinic hours 9 (5.9) 3 (7.7) 12 (6.3)
Long waiting time 5 (3.3) 5 (12.8) 10 (5.2)
Perception of health
improvement
44 (28.9) 10 (25.6) 54 (28.3)
Poor health 7 (4.6) 3 (7.7) 10 (5.2)
Lack of support by partner 19 (13.9) 4 (11.1) 23 (13.4)
Use of traditional medicine 14 (9.2) 4 (10.3) 18 (9.4)
Drug toxicity 2 (1.3) 5 (12.8) 7 (3.7)
LFU, loss to follow-up; ART, Antiretroviral therapy.
*178 Pre-ART and 49 ART patients only provided information on reasons for defaulting.
23 Pre-ART and 6 ART patients aged <15 years were excluded.
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